ArticleClinical ophthalmology (Auckland, N.Z.)2012
Proliferative vitreoretinopathy: current and emerging treatments.
Article in Clinical ophthalmology (Auckland, N.Z.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06425419 (The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy), which is not on this map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial.Scientific reports · 2024Trial
- Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations.Scientific reports · 2021Trial
- Adjuvant mitomycin C during vitrectomy in young adults with primary nontraumatic rhegmatogenous retinal detachment and grade C proliferative vitreoretinopathy.BMC ophthalmology · 2026Article
- Prevention of postoperative proliferative vitreoretinopathy in complex retinal detachments with serial intravitreal methotrexate injections.International journal of retina and vitreous · 2026Article
- The efficacy of the three-port bimanual technique for direct perfluorocarbon liquid-silicone oil exchange in vitrectomy for the treatment of advanced proliferative vitreoretinopathy.BMC ophthalmology · 2025Article
- Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment.Investigative ophthalmology & visual science · 2025Article
- Treatment Efficacy of a Dual Release of Aflibercept and Dexamethasone From a Single Hydrogel Drug Delivery System in a Rodent Model.Translational vision science & technology · 2025Article
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- A pilot study of intraoperative melphalan to prevent recurrent PVR: the IOMPVR study.International journal of retina and vitreous · 2025Article
- Multikinase inhibition-mediated proliferative vitreoretinopathy therapy by nanoparticles in rabbits.Molecular vision · 2025Article
- A multicenter study on rates and risk factors of proliferative vitreoretinopathy in a low-income economy.PloS one · 2025Article
- As shown hesperidin suppresses TGF-β2-induced proliferation and epithelial-mesenchymal transition of retinal pigment epithelial cells.Journal of molecular histology · 2024Article
- Proliferative Vitreoretinopathy in Retinal Detachment: Perspectives on Building a Digital Twin Model Using Nintedanib.International journal of molecular sciences · 2024Review
- Advancements in Therapeutic Approaches for Proliferative Vitreoretinopathy: A Comprehensive Review.Cureus · 2024Review
- Bone morphogenetic protein 6 (BMP6) antagonises experimental proliferative vitreoretinopathy established by TGF-β2 stimulation in retinal pigment epithelial cells through modulation of the p38 and JNK MAPK pathways.Cell and tissue research · 2024Article
- The Effect of Anti-Autotaxin Aptamers on the Development of Proliferative Vitreoretinopathy.International journal of molecular sciences · 2023Article
- Proliferative Vitreoretinopathy: A Reappraisal.Journal of clinical medicine · 2023Review
- Article
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative vitreoretinopathy is a disease process that follows the proliferation of ectopic cell sheets in the vitreous and/or periretinal area, causing periretinal membrane formation and traction, in patients with rhegmatogenous retinal detachments. Currently, vitreous surgery is the standard treatment; however, the results aren't satisfactory given the vision loss that ensues and that redetachment is relatively common. It is becoming clearer that there exists an interplay between various cytokines/growth factors, matrix proteins, and the different cell types that drive the undesirable formation of periretinal membranes. This fundamental understanding is aiding in identifying different adjunct agents that can block the cellular events intrinsic to proliferative vitreoretinopathy. In this review, we describe the current understanding on the pathogenesis and discuss how the fundamental understanding of the biochemical/molecular events is instrumental in developing the novel treatment strategies that are also highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.